Vanessa Blumer
A5079460814- Mechanical Circulatory Support Devices
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Cardiac pacing and defibrillation studies
- Transplantation: Methods and Outcomes
- Cardiovascular Function and Risk Factors
- Cardiovascular Issues in Pregnancy
- Cardiac Valve Diseases and Treatments
- Hemodynamic Monitoring and Therapy
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
- Renal Transplantation Outcomes and Treatments
- Acute Myocardial Infarction Research
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Congenital Heart Disease Studies
- Organ Donation and Transplantation
- Pharmaceutical Economics and Policy
- Viral Infections and Immunology Research
- Health and Medical Research Impacts
- Medication Adherence and Compliance
- Sex and Gender in Healthcare
Alaska Heart and Vascular Institute
2023-2025
Inova Fairfax Hospital
2023-2025
Cleveland Clinic
2022-2024
Bon Secours Heart & Vascular Institute
2024
Columbia University Irving Medical Center
2021-2024
Brigham and Women's Hospital
2024
Twitter (United States)
2024
Mount Sinai Hospital
2024
Inova Health System
2024
Duke Medical Center
2019-2023
Background: Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role extended thromboprophylaxis after hospital discharge is unclear. Objective: To determine whether anticoagulation superior to placebo in reducing death and thromboembolic complications among patients discharged hospitalization. Design: Prospective, randomized, double-blind, placebo-controlled clinical trial. (ClinicalTrials.gov: NCT04650087) Setting: Done during 2021 2022 127 U.S....
Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% 50% despite recent scientific advances. Age is a nonmodifiable risk factor for in patients with cardiogenic and often considered the decision-making process eligibility various therapies. Older adults have been largely excluded from analyses therapeutic options shock. As result, association advanced age worse focused strategies assessment management this high-risk growing population are...
Hemodynamic derangements are defining features of cardiogenic shock. Randomized clinical trials have examined the efficacy various therapeutic interventions, from percutaneous coronary intervention to inotropes and mechanical circulatory support (MCS). However, hemodynamic management in shock has not been well-studied. This State-of-the-Art review will provide a framework for shock, including description four phases initial 'Rescue' 'Optimization', 'Stabilization' 'de-Escalation or Exit...
In recent years, there have been significant advancements in the understanding, risk-stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic device-based therapies for CS, short-term mortality remains as high 50%. Most efforts research focused on CS related to acute myocardial infarction, even though heart failure (HF-CS) accounts >50% cases. There is a paucity high-quality evidence support standardized clinical practices approach HF-CS. addition, an unmet...
Abstract Aims Non‐alcoholic fatty liver disease leads to progressive fibrosis and appears be a frequent co‐morbid in heart failure with preserved ejection fraction (HFpEF). It is well known that severity predicts future liver‐related morbidity mortality, but its impact on outcomes patients HFpEF remains unknown. This analysis aimed describe the prevalence of fibrosis, as assessed using surrogate biomarkers, association such biomarkers predicting clinical these patients. Methods results...
Hospitalization for heart failure (HF) constitutes a major healthcare and economic burden. Trends characteristics of hospitalizations HF the recent years are not clear. We sought to determine trends hospitalization in United States.